SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending as investors react to the company's annual shareholder meeting and news regarding a potential acquisition of eBay, sparking intense debate over whether these developments signal a strategic pivot or further dilution. The community remains deeply divided, with bulls highlighting long-term turnaround efforts while bears and frustrated retail holders point to stagnant price action and past failed squeeze predictions.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is seeing heightened activity as the community debates whether recent competitive headlines and sector volatility signal a structural threat or a temporary accumulation opportunity. Traders remain fixated on the stock's ability to reclaim the $200 level, with many viewing the ongoing price consolidation as a test of conviction amidst the broader AI infrastructure arms race.

Vera Therapeutics, Inc. is a clinical stage biotechnical company which engages in the development and commercialization of transformative treatments for immunological diseases. The company was founded by Marshall Fordyce in May 2016 and is headquartered in Brisbane, CA.

Vera Therapeutics Inc - Ordinary Shares - Class A

Vera Therapeutics is trending as investors react to a significant clinical data milestone regarding the stabilization of kidney function for its lead drug, Atacicept, alongside optimism surrounding its regulatory pathway. The community is actively debating the stock's potential for a short squeeze due to high short interest, while institutional investors closely monitor its competitive positioning in the IgA nephropathy market.

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the development of imdusiran (AB-729), proprietary, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic, and AB-101, proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). The company was founded on October 6, 2005 and is headquartered in Warminster, PA.

Arbutus Biopharma Corp

Arbutus Biopharma is currently capturing investor attention following the FDA's decision to grant fast track designation to its lead chronic Hepatitis B candidate, imdusiran. The community is actively debating the stock's long-term valuation in light of this clinical progress, alongside ongoing patent litigation catalysts against major pharmaceutical firms and potential strategic takeover interest.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is surging as investors speculate on a potential buyout amid strong commercial growth from its Briumvi franchise and recent expansion into new indications like schizophrenia. The community is actively discussing the stock's impressive momentum, significant short interest, and the removal of potential acquisition barriers as primary drivers for a potential future premium transaction.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending as investors react to a solid earnings report and raised revenue guidance, fueling community speculation about a potential buyout or major partnership as the company approaches self-sustainability. Discussions remain heavily focused on the blockbuster potential of Recorlev and the upcoming Phase 3 development of their once-weekly injectable levothyroxine candidate, XP-8121.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending due to strong upward momentum driven by sector rotation into biotech and intense investor anticipation surrounding key clinical catalysts, including upcoming maintenance trial results. The community is actively debating the potential for a strategic partnership or buyout, as shareholders closely watch the company's progress in the competitive GLP-1 weight-loss market.

Groupon, Inc. engages in the global scaled two-sided marketplace that connects consumers to merchants. It operates through the North America and International geographical segments. The company was founded by Andrew D. Mason, Eric Paul Lefkofsky, and Bradley A. Keywell in October 2008 and is headquartered in Chicago, IL.

Groupon Inc

Groupon is experiencing a significant surge in momentum driven by a combination of index rebalancing, active share buybacks, and high short interest that has led the community to draw parallels to previous parabolic short squeeze setups. Traders are closely monitoring a tight, institutional-heavy float as they anticipate that sustained upside could force short sellers to cover, potentially accelerating price movement toward key resistance levels.

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.

Immix Biopharma Inc

Immix Biopharma is trending as institutional interest surges following a $14 price target initiation by Mizuho and confirmed Breakthrough Therapy Designation for NXC-201. The community is actively discussing the potential for a strategic buyout or accelerated BLA timeline, with many investors focusing on the company's differentiated ex vivo CAR-T platform as a major differentiator in the AL amyloidosis space.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is gaining significant investor attention as recent Phase 3 data and potential FDA approval milestones for its lead psychedelic program, COMP360, strengthen the company's commercial outlook for treatment-resistant depression. Community discussion is heavily focused on the stock's role as a first-mover in a nascent sector, with many participants tracking institutional interest, the upcoming NDA submission, and the potential for a transformative impact on psychiatric medicine.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$ALTL
Current Stock Price: $44.25
Contracts to trade: $45 ALTL May 15 2026 Call
Entry: $0.67
Exit: $1.13
ROI: 69%
Hold ~27 days

Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

AI Powered Insights Get daily AI-generated picks that are primed to give you an edge. Join thousands of users who are getting smarter with our insights. Join thousands of users getting insightful AI-powered content delivered daily. 100% Free * No Credit Card Required * Disclaimer: The information provided is for educational purposes only and should not be considered professional advice.

Dailypickai

DailyPickAI

StockTwits Web

Pacer Funds Trust - Pacer Lunt Large Cap Alternator ETF


Current Stock Price: $44.25
Contracts to trade: $45 ALTL May 15 2026 Call
Entry: $0.67
Exit: $1.13
ROI: 69%
Hold ~27 days

Shared as daily free alerts and for educational purposes only. 